The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

@article{Pulsipher2014TheAO,
  title={The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.},
  author={Michael A Pulsipher and Bryan Langholz and Donna Wall and Kirk R Schultz and Nancy J. Bunin and William L Carroll and Elizabeth A. Raetz and Sharon C Gardner and Julie M. Gastier-Foster and Denise Howrie and Rakesh K Goyal and James G. Douglas and Michael Borowitz and Yvonne J. Barnes and David Teachey and Candace Taylor and Stephan A. Grupp},
  journal={Blood},
  year={2014},
  volume={123 13},
  pages={2017-25}
}
Sirolimus has activity against acute lymphoblastic leukemia (ALL) in xenograft models and efficacy in preventing acute graft-versus-host disease (aGVHD). We tested whether addition of sirolimus to GVHD prophylaxis of children with ALL would decrease aGVHD and relapse. Patients were randomized to tacrolimus/methotrexate (standard) or tacrolimus/methotrexate… CONTINUE READING